New Research Article: The impact of pharmaceutical M&A on innovation

by Hanna | Jul 8, 2024 | Blog Post

Mergers and acquisitions (M&A) play a unique and fundamental role in the development of new treatments and cures across the pharmaceutical ecosystem. A research article published yesterday, “The impact of pharmaceutical M&A on innovation: Insights from the...

Forbes Opinion – Former FTC Official: FTC & DOJ Must Return to a Balanced, Bipartisan Approach to M&A

by Hanna | Jul 3, 2024 | Blog Post

In a recent Forbes op-ed, former Federal Trade Commission (FTC) general counsel Alden Abbott outlines the lack of evidence behind the FTC and Department of Justice’s (DOJ) recent shift toward a more aggressive approach to challenging mergers and acquisitions...

Innovations Advanced by M&A: Breakthroughs for a Rare Blood Disease

by Hanna | Jun 26, 2024 | Blog Post, Innovations Advanced by M&A

This blog is another installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series here....

FTC Budget Hearing Recap: Policymakers Express Concern About Agency’s Approach to M&A

by Hanna | Jun 12, 2024 | Blog Post

Recently, Federal Trade Commission (FTC) Chair Lina Khan appeared before the House Appropriations Committee Subcommittee on Financial Services and General Government to discuss the Agency’s proposed budget for the upcoming fiscal year. During her testimony, Chair Khan...

Innovations Advanced by M&A: An Innovative CAR-T Therapy for Blood Cancer

by Hanna | Jun 5, 2024 | Blog Post, Innovations Advanced by M&A

This blog is another installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series...